Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 22, 2026

What Is Really Destroying Social Security and What Congress Could Actually Do to Fix It

View original at finance.yahoo.com
What Is Really Destroying Social Security and What Congress Could Actually Do to Fix It Quick Read Social Security’s $2.5 trillion trust fund is invested in special-issue government bonds as required by law; the real crisis is demographic—fewer workers supporting more retirees as baby boomers retire, with the combined…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Social Security is not going broke because politicians raided the piggy bank; the trust fund's $2.5 trillion in reserves is properly invested in special-issue government bonds, exactly as the law requires

    60% confidence
  • The real problem is slower and harder to fix: the math of an aging country is quietly grinding the program toward a cliff

    60% confidence
  • The combined trust fund depletes in 2034, leaving incoming revenue to cover only 81% of scheduled benefits

    60% confidence
  • High earners stop contributing once their wages cross the threshold, which is why lifting the cap is a perennial reform proposal

    60% confidence

Data points we hold from this source

Social Security Administration · benefit coverage after depletion81 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com